2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Microbiome, Clinical Practice (Health Services and Quality), Practice Models, Quality Improvement, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2439 What change in chimerism can be interpreted with confidence: Impact of analytical variability after allogeneic hematopoietic cell transplantation

Olga Timofeeva, PhD, Alan Sanfilippo2, Anna Greenshields, PhD3, Ahmed Mostafa4, William Hoffman5, Rajesh Parmar6, Neng Yu7, Ketevan Gendzekhadze, PhD8, Lee Ann Baxter-Lowe, PhD9, Reut Hod Dvorai10
1 UCLA, Los Angeles, California, United States
2 Piedmont Transplant Institute, Atlanta, Georgia, United States
3 Dalhousie University, Halifax, Nova Scotia, Canada
4 Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada
5 UPMC Harrisburg, Harrisburg, Pennsylvania, United States
6 UCLA, Los Angeles, California, United States
7 UMass Chan Medical School, Worcester, Massachusetts, United States
8 City of Hope, Irwindale, California, United States
9 Children's Hospital of Los Angeles, Los Angeles, California, United States
10 SUNY Upstate Medical University, Syracuse, New York, United States

Background: Clinical decisions after allogeneic hematopoietic cell transplantation (HCT), including immunosuppression adjustment, repeat testing, and consideration of donor lymphocyte infusion (DLI), are frequently guided by longitudinal changes of approximately 5 percentage points in donor or recipient chimerism. Whether changes of this magnitude can be confidently distinguished from analytical variation has not been systematically evaluated.

Methods: We analyzed 7 years (2018–2024) of American Society for Histocompatibility and Immunogenetics (ASHI) Engraftment Monitoring proficiency testing data comprising 14 surveys with 47–58 participating laboratories. Inter-laboratory variability of short tandem repeat (STR)- and next-generation sequencing (NGS)-based assays was compared across the 0–50% minor DNA fraction range. To evaluate the ability of individual laboratories to measure longitudinal changes, we identified paired specimens from the same donor-recipient pair representing either a true ~5-percentage-point change or no true change in minor DNA fraction and compared each laboratory's reported results across both specimens. Laboratory-specific performance was further assessed by modeling complete testing histories to estimate the probability that analytical variation alone would reverse the apparent direction of a true 5-percentage-point change.

Results: NGS demonstrated lower inter-laboratory variability than STR across the entire minor DNA fraction range (weighted SD, 1.19 vs. 2.22 percentage points). For specimen pairs representing a true ~5-percentage-point change, NGS laboratories consistently measured changes of 4–6 percentage points, whereas STR laboratories reported changes ranging from 0–9 percentage points, including instances in which analytical variation reversed the apparent direction of change. For specimen pairs with no true change, NGS laboratories reported within-laboratory differences of 0–3 percentage points, compared with 0–7 percentage points for STR laboratories. Whole-range modeling demonstrated that no NGS laboratory had an estimated >5% probability of reversing the ordering of two results differing by 5 percentage points, compared with 27.3% of STR laboratories.

Conclusions: Analytical variability can substantially influence the interpretation of the small longitudinal chimerism changes that commonly guide post-transplant clinical management. Incorporating laboratory-specific analytical precision into the interpretation of serial chimerism results may improve confidence in distinguishing true biological change from analytical variation and support more informed clinical decision-making.

Olga Timofeeva, PhD: No relevant conflicts of interest to declare.